Bromgeksin Obolenskoe - instructions for use, doses, side effects, contraindications

Excipients: sugar milk (lactose), microcrystalline cellulose, magnesium stearate, sugar (sucrose), polyvinylpyrro-lidone (povidone), magnesium basic carbonate, aerosil (silicon dioxide colloid), talc, titanium dioxide, beeswax, sunflower oil, food coloring red or quinoline yellow.

Description:

The tablets covered with a cover, yellow (8 mg) or red (4 mg) color, round, biconcave. Two layers are visible on the cross-section.

Pharmacotherapeutic group:Mucolytic agent

ATX: & nbsp

R.05.C.B Mucolytics

R.05.C.B.02 Bromhexine

Pharmacodynamics:

The drug has mucolytic (secretolitic) and expectorant action. Mucolytic effect is associated with depolymerization and liquefaction of mucoprotein and mucopolysaccharide fibers. Bromhexine has a weak antitussive effect. Stimulates the production of endogenous surfactant, which ensures the stability of alveolar cells in the process of breathing. Clinical effect is manifested after 2-5 days from the beginning of treatment with the drug.

Pharmacokinetics:

Ingestion bromohexine almost completely (99%) is absorbed within 30 minutes. Bioavailability is 80% (the effect of "first passage" through the liver). In the plasma bromohexine binds to proteins, penetrates the blood-brain and placental barrier. In the liver bromohexine is subjected to demethylation and oxidation. The half-life is 15 hours due to slow reverse diffusion from the tissues. It is excreted by the kidneys. When chronic renal failure is disrupted by the release of metabolites of bromhexine. With repeated use bromohexine can cumulate.

Indications:

Bronchopulmonary diseases, accompanied by the formation of sputum increased, viscosity (bronchial asthma,cystic fibrosis, tuberculosis, pneumonia, tracheobronchitis, obstructive bronchitis, bronchiectasis, pulmonary emphysema, pneumoconiosis), pre- and postoperative period.

Contraindications:

Increased sensitivity to the components of the drug;
Pregnancy (1st trimester);
Lactation period;
Peptic ulcer (at the stage of exacerbation);
Children under 6 years.

Carefully:

Bromhexine should be used in weakened patients with gastric bleeding in history, renal and / or liver failure, as well as patients with bronchial disease, accompanied by excessive accumulation of secretions.

Dosing and Administration:

Bromhexine take inside regardless of food intake. Adults appoint 8-16 mg 3-4 times a day; from 6 to 14 years-8mg 3 times a day. The course of treatment is from 4 to 28 days.

During the treatment it is recommended to use a sufficient amount of liquid that supports the secretolitic action of bromhexine.

In children, treatment should be combined with postural drainage or vibration massage of the chest, facilitating the evacuation of secretions from the bronchi.

Side effects:

Rarely, with prolonged use of the drug, nausea, vomiting, dyspepsia, dizziness,headache, exacerbation of peptic ulcer, allergic reactions (skin rash, rhinitis, etc.), increasing the level of "liver" transaminases in the blood serum. In these cases, the drug should be discontinued.

Overdose:

Symptoms: nausea, vomiting, diarrhea, dyspeptic disorders.

Treatment: artificial vomiting, gastric lavage (in the first 1-2 hours after administration).

Interaction:

Bromhexine can be administered simultaneously with other drugs used in the treatment of bronchopulmonary diseases.

Bromhexine Do not prescribe concomitantly with medicines containing codeine, as this makes it difficult to evacuate diluted sputum.

Bromhexine contributes to the penetration of antibiotics (erythromycin, cephalexin, oxytetracycline) into the lung tissue.

Bromhexine not compatible with alkaline solutions.

Form release / dosage:

The coated tablets are 4 mg and 8 mg.

Packaging:

10 or 20 tablets per contour cell package;

By 1, 2, 3, 4, 5 or 10 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

In a dry, dark place, out of the reach of children.

Shelf life:3 years.

Terms of leave from pharmacies:Without recipe

Registration number:LS-000343

Date of registration:27.04.2010

Expiration Date:Unlimited

The owner of the registration certificate:OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia

Manufacturer: & nbsp

OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia

Information update date: & nbsp25.02.2017

Illustrated instructions

Instructions

Bromgeksin Obolenskoe (Bromhexine Obolenskoe)